ED
CKPT

Exane Derivatives’s Checkpoint Therapeutics CKPT Stock Holding History

Exane Derivatives’s Portfolio CKPT Stock Details CKPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		$1.66K Sell
161
-2,724
-94% -$35.7K ﹤0.01% 460
2022
Q1 		$51.1K Sell
2,885
-241
-8% -$5.18K 0.01% 567
2021
Q4 		$97.2K Sell
3,126
-1,697
-35% -$56.2K 0.02% 444
2021
Q3 		$159K Buy
+4,823
New +$143K 0.04% 447

Other funds holding CKPT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JSMC
Jess S. Morgan & Co Los Angeles, California $115M AUM 16.65% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return
EL
EMFO LLC Weston, Florida $112M AUM 18.79% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Exane Derivatives's CKPT Position: Q2 2022 in Review

Exane Derivatives reduced its Checkpoint Therapeutics (CKPT) stake by 94% in Q2 2022, selling an estimated $35.7K and leaving 161 shares worth $1.66K. The position accounts for ﹤0.01% of the portfolio, ranked #460.

Exane Derivatives first reported a position in CKPT in Q3 2021 and has held it in 4 quarters since. The position peaked at $159K in Q3 2021. 62 funds tracked by Wall St. Rank hold CKPT as of Q2 2022.

  • Exane Derivatives held 161 shares of Checkpoint Therapeutics worth $1.66K as of Q2 2022.
  • Exane Derivatives sold 2,724 Checkpoint Therapeutics shares in Q2 2022, an estimated $35.7K.
  • Checkpoint Therapeutics made up ﹤0.01% of Exane Derivatives's portfolio in Q2 2022, its #460 holding.
  • Exane Derivatives first reported a position in Checkpoint Therapeutics in Q3 2021 and has held it in 4 quarters since.
  • Exane Derivatives's Checkpoint Therapeutics position peaked at $159K in Q3 2021.
  • 62 funds tracked by Wall St. Rank held Checkpoint Therapeutics as of Q2 2022.

Based on Exane Derivatives's 13F filing for Q2 2022, filed 12 Jul 2022.